Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013
December 07, 2013 at 11:03 AM EST
Seattle Genetics (Nasdaq: SGEN ) today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including acute
